Patents Assigned to Oxford Biomedica (UK) Limited
-
Publication number: 20090047307Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.Type: ApplicationFiled: March 20, 2008Publication date: February 19, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
-
Publication number: 20090017532Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: August 6, 2008Publication date: January 15, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20080279854Abstract: Canine and feline 5T4 polypeptide sequences and nucleotide sequences encoding them are provided. A vector system comprising a nucleic acid encoding 5T4 and a 5T4-specific agent are also provided.Type: ApplicationFiled: July 7, 2008Publication date: November 13, 2008Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Kevin Myers, Noel Drury, Miles Carroll
-
Publication number: 20080274542Abstract: Canine and feline 5T4 polypeptide sequences and nucleotide sequences encoding them are provided. A vector system comprising a nucleic acid encoding 5T4 and a 5T4-specific agent are also provided.Type: ApplicationFiled: July 8, 2008Publication date: November 6, 2008Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Kevin Myers, Noel Drury, Miles Carroll
-
Patent number: 7419829Abstract: The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.Type: GrantFiled: June 21, 2004Date of Patent: September 2, 2008Assignee: Oxford BioMedica (UK) LimitedInventors: Kyri Mitrophanous, Jonathan Rohll, James Miskin, Susan Marie Kingsman
-
Publication number: 20080175819Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: ApplicationFiled: August 6, 2007Publication date: July 24, 2008Applicant: Oxford BioMedica (UK) LimitedInventors: Alan J. Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Susan M. Kingsman, Kevin A. Myers
-
Publication number: 20080118481Abstract: The invention relates to the exploitation of the migratory behaviour of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the mononuclear phagocyte to a target area.Type: ApplicationFiled: October 4, 2006Publication date: May 22, 2008Applicant: Oxford BioMedica (UK) LimitedInventors: Claire E. Lewis, Adrian L. Harris, Julian M. Marshall
-
Publication number: 20070298055Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: ApplicationFiled: March 15, 2007Publication date: December 27, 2007Applicant: Oxford BioMedica (UK) LimitedInventors: Miles Carroll, Kevin Myers
-
Publication number: 20070281898Abstract: The present invention relates to a retroviral vector system comprising a therapeutic gene wherein said retroviral vector system is pseudotyped with at least part of a heterologous envelope protein or a mutant, variant or homologue thereof and wherein said therapeutic gene is downstream of an internal promoter.Type: ApplicationFiled: March 28, 2007Publication date: December 6, 2007Applicant: Oxford Biomedica (UK) LimitedInventors: Andrew Slade, Susan Kingsman
-
Patent number: 7303910Abstract: A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.Type: GrantFiled: April 30, 2004Date of Patent: December 4, 2007Assignee: Oxford Biomedica (UK) LimitedInventors: Christopher Robert Bebbington, Susan Mary Kingsman, Mark Uden, Alan John Kingsman, Kyriacos Mitrophanos
-
Publication number: 20070259400Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: April 26, 2006Publication date: November 8, 2007Applicant: Oxford BioMedica (UK) LimitedInventors: Alan Kingsman, Susan Kingsman, Christopher Bebbington, Miles Carrol, Fiona Ellard, Kevin Myers
-
Patent number: 7276488Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: GrantFiled: January 29, 2002Date of Patent: October 2, 2007Assignee: Oxford Biomedica (UK) LimitedInventors: Alan J. Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Susan M. Kingsman, Kevin A. Myers
-
Publication number: 20070161080Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: July 7, 2006Publication date: July 12, 2007Applicant: Oxford BioMedica (UK) LimitedInventors: Alan Kingsman, Susan Kingsman, Christopher Bebbington, Miles Carrol, Fiona Ellard, Kevin Myers
-
Publication number: 20070128164Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: ApplicationFiled: September 18, 2006Publication date: June 7, 2007Applicant: Oxford BioMedica (UK) LimitedInventors: Miles Carroll, Kevin Myers
-
Patent number: 7198784Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.Type: GrantFiled: September 11, 2003Date of Patent: April 3, 2007Assignee: Oxford Biomedica (UK) LimitedInventors: Alan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous
-
Patent number: 7189562Abstract: The invention relates to the exploitation of the migratory behavior of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the munonuclear phagocyte to a target area.Type: GrantFiled: October 8, 1997Date of Patent: March 13, 2007Assignee: Oxford BioMedica (UK) LimitedInventors: Claire E. Lewis, Adrian L. Harris, Julian M Marshall
-
Publication number: 20070014808Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: ApplicationFiled: November 22, 2005Publication date: January 18, 2007Applicant: Oxford BioMedica (UK) LimitedInventors: Miles Carroll, Kevin Myers
-
Publication number: 20060286634Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: April 25, 2006Publication date: December 21, 2006Applicant: Oxford Biomedica (UK) LimitedInventors: Susan Kingsman, Christopher Bebbington, Fiona Ellard, Miles Carroll, Kevin Myers
-
Patent number: 7148035Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: GrantFiled: March 24, 2000Date of Patent: December 12, 2006Assignee: Oxford Biomedica (UK) LimitedInventors: Miles William Carroll, Kevin Alan Myers
-
Patent number: 6969598Abstract: A method for producing viral vectors is described using packaging and producer cell lines is described. The producer cell comprises: (i) a first nucleotide sequence (NS) encoding a toxic viral envelope protein operably linked to a promoter; wherein the promoter is operably linked to at least one copy of a TRE; (ii) a second NS wherein the second NS comprises a sequence encoding a tetracycline modulator; (iii) a third NS encoding a retrovirus nucleocapsid protein; and (iv) a fourth NS comprising a retroviral sequence capable of being encapsidated in the nucleocapsid protein such that the retroviral vector particle titre obtainable from the producer cell is regulatable by tetracycline and an initial stimulus with sodium butyrate or functional analogues thereof.Type: GrantFiled: April 30, 2002Date of Patent: November 29, 2005Assignees: Oxford Biomedica (UK) Limited, The University of North Carolina at Chapel HillInventors: John C. Olsen, Kyriacos Andreou Mitrophanous, Jonathan Rohll, Alan John Kingsman, Fiona Margaret Ellard